Publications
62
Citations
3,478
Est. group size
—
Recurring co-author estimate
Active years
19
Publishing since 2008
This researcher works on cancer treatment and biology, with recent focus on CAR-T cell therapy (a treatment that reprograms a patient's own immune cells to attack cancer) for blood cancers like leukemia and lymphoma, as well as genetic studies of lung cancer and drug resistance mechanisms. Work spans clinical trials of new cell therapies, genomic profiling of tumors, and studies of how cancers evolve to resist targeted drugs.
Publication output was fairly steady at 2-4 per year for most of the past decade, with a sharp but temporary spike in 2023 likely tied to a cluster of related clinical trial reports.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Author Correction: BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
Nature · 2026
- Varnimcabtagene autoleucel in relapsed or refractory B-cell malignancies
Blood Immunology & Cellular Therapy · 2025
- Varnimcabtagene autoleucel (IMN-003A) in phase-2 first-in-India industry study for relapsed refractory B cell malignancies: B-all pediatric subanalysis (imagine study)
Pediatric Hematology Oncology Journal · 2023
- P1364: PHARMACOKINETIC PROFILE OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A), FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T CELL THERAPY FOR PATIENTS WITH RELAPSED/ REFRACTORY B CELL MALIGNANCIES (IMAGINE STUDY)
HemaSphere · 2023
- Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
2023
- Varnimcabtagene Autoleucel (IMN-003A): Differences in T Cell Subset Phenotype in B-ALL and B-NHL Cohorts Did Not Influence Efficacy Outcomes in the Phase-2 Study (IMAGINE)
Blood · 2023
- Cytokine Profile Following Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies in the First-in-India Industry Phase-2 Study (IMAGINE)
Blood · 2023
- Varnimcabtagene Autoleucel (IMN-003A): Pharmacokinetic Profile with Predominant Naïve and Central Memory Phenotype Demonstrates Sustained In Vivo Persistence and Durable Responses in a First-in-India Industry Phase-2 Study (IMAGINE)
Blood · 2023
- Blood×3
- Journal of Thoracic Oncology×3
- Nature×2
- Nature Genetics×2
- International Journal of Otorhinolaryngology and Head and Neck Surgery×2
- Julie M. Gastier‐Foster
Medicine · The Ohio State University
- Shalini C. Reshmi
Medicine · The Ohio State University
- Susan I. Colace
Medicine · The Ohio State University
- Chunhua Song
Medicine · The Ohio State University
- Nyla A. Heerema
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile